Which blood thinner works best after heart device implant? new trial aims to find out
NCT ID NCT03568890
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two approaches—short-term anticoagulation (stronger blood thinners) versus antiplatelet therapy (milder blood thinners)—to prevent clots on a device placed in the heart's left atrial appendage. The trial involves 510 adults who have had this procedure. The goal is to see which strategy better reduces device thrombosis, stroke, and bleeding over 60 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Blood thinners (rivaroxaban, dabigatran, apixaban, edoxaban, clopidogrel, or low-dose aspirin)
What this could lead to
If it works, this could show that short-term blood thinners are better at preventing dangerous clots on the device after a heart procedure, reducing stroke risk.
What could go wrong
This is a phase 4 trial, so the drugs are already approved, but the best strategy for this specific use is still unknown. Results may not apply to all patients or devices.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Josep Rodes-Cabau
Québec, Quebec, G1V 4G5, Canada